北京：推进北京普惠健康保更好发展，加强对创新药械的保障支持

Core Viewpoint - The Beijing Municipal Medical Insurance Bureau and the Beijing Financial Supervision Bureau have jointly released measures to support the high-quality development of commercial health insurance, focusing on product innovation and data utilization [1][2]. Group 1: Data Utilization and Innovation - The measures propose to advance the development and utilization of medical insurance data, establishing a data-sharing mechanism for medical expenses, health check-ups, and imaging tests, while ensuring data security and compliance [1]. - Medical institutions and pharmaceutical companies are encouraged to provide information on innovative drugs and clinical trial data for commercial insurance companies to aid in product pricing and risk control [1]. Group 2: Support for Product Innovation - The measures support the innovation of commercial insurance products, including disease prediction and intervention insurance, specific disease insurance for cardiovascular diseases and rare diseases, as well as insurance for innovative drugs and clinical liability [2]. - There is encouragement for the development of group health insurance products, commercial nursing insurance, and income loss insurance due to disability, along with support for eligible companies to engage in dividend-type long-term health insurance [2]. - The measures also promote the development of medical insurance products tailored for foreign personnel in China, streamlining the insurance and claims processes while enhancing health management services [2]. Group 3: Development of Inclusive Health Insurance - The measures aim to enhance the development of inclusive health insurance in Beijing by optimizing product protection levels and service rights, dynamically adjusting special drug lists, and strengthening support for innovative drugs and devices [2]. - There is an exploration of improving product sales mechanisms to better leverage the supplementary protection function of inclusive commercial health insurance [2].